- You can view the full Medivation Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The company has spent $600 million weighing a potential breakup.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.